India · Delayed Price · Currency is INR Nectar Lifesciences Statistics
Total Valuation
BOM:532649 has a market cap or net worth of INR 2.22 billion. The enterprise value is 971.29 million.
| Market Cap | 2.22B |
| Enterprise Value | 971.29M |
Important Dates
The last earnings date was Saturday, May 30, 2026.
| Earnings Date | May 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 194.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -2.54% |
| Shares Change (QoQ) | -9.87% |
| Owned by Insiders (%) | 56.26% |
| Owned by Institutions (%) | 6.72% |
| Float | 82.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.59
| Current Ratio | 9.59 |
| Quick Ratio | 6.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.43 |
Financial Efficiency
Return on equity (ROE) is -7.46% and return on invested capital (ROIC) is -6.36%.
| Return on Equity (ROE) | -7.46% |
| Return on Assets (ROA) | -2.42% |
| Return on Invested Capital (ROIC) | -6.36% |
| Return on Capital Employed (ROCE) | -8.75% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.64M |
| Employee Count | 1,786 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -305.32M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -47.85% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -47.85% |
| 50-Day Moving Average | 12.20 |
| 200-Day Moving Average | 14.26 |
| Relative Strength Index (RSI) | 43.04 |
| Average Volume (20 Days) | 21,524 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -517.54M |
| Pretax Income | -878.79M |
| Net Income | -2.93B |
| EBITDA | -289.51M |
| EBIT | -517.54M |
| Earnings Per Share (EPS) | -13.40 |
Balance Sheet
The company has 1.25 billion in cash and n/a in debt, with a net cash position of 1.25 billion.
| Cash & Cash Equivalents | 1.25B |
| Total Debt | n/a |
| Net Cash | 1.25B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.82B |
| Book Value Per Share | 28.98 |
| Working Capital | 2.59B |
Cash Flow
In the last 12 months, operating cash flow was -3.49 billion and capital expenditures -122.74 million, giving a free cash flow of -3.61 billion.
| Operating Cash Flow | -3.49B |
| Capital Expenditures | -122.74M |
| Depreciation & Amortization | 228.03M |
| Net Borrowing | -6.36B |
| Free Cash Flow | -3.61B |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BOM:532649 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.54% |
| Shareholder Yield | 2.54% |
| Earnings Yield | -131.79% |
| FCF Yield | -162.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 12, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Nov 12, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |